⚑Today
✨Today's leadDoctors Complete First Bone Marrow Transplant From Deceased Donor for Non-Malignant Disease🎈For kidsSouth Carolina tract beside wildlife refuge to be permanently conserved🌿NatureFormer ocean liner S.S. United States becomes the world's largest artificial reef⚽SportsLindy Duncan wins her first LPGA title on attempt 222🎨Culture & ideasA Lost Altdorfer Landscape Surfaces After 70 Years Privately HeldπŸ”¬Science & healthPeople who control HIV without treatment may help find a cureπŸ’›KindnessA laid-off man began mowing lawns for free and 2,100 volunteers joinedπŸ›οΈPoliticsLos Angeles bans oil drilling after a decade of neighborhood pressureπŸš€ProgressPhiladelphia repaired a collapsed interstate in 12 days

Incyte cancer drug shows lasting tumor responses in some pancreatic cancer patients

STAT 26 October 2026 2 min read

In short

  • Incyte's targeted drug was used alongside chemotherapy.
  • The company reported lasting tumor responses in certain patients.
  • The results were presented at ESMO, the European Society for Medical Oncology congress.

Why it's good news

Pancreatic cancer is among the hardest cancers to treat, so lasting responses in any patient group matter. The findings are the company's account as presented at ESMO, and the source gives no detail on patient numbers or trial stage. Readers should wait for independent review before reading more into them.

Advertisement

From STAT

A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.

Read the full story at STAT Opens the publisher's site in a new tab.

Ask this story

An AI model answers from the material behind this story only, with a link to the source. Your question is sent to our AI provider and isn't stored. See Privacy.

More like this

Advertisement
AdMobile anchor